PDF(Pubmed)
Abstract：
BACKGROUND: This study evaluated the safety and effectiveness of combining intravitreal brolucizumab injection with sub-tenon\'s capsule triamcinolone acetonide injection (STTA) during the loading phase for polypoidal choroidal vasculopathy (PCV).
METHODS: In this retrospective observational study, untreated patients with PCV receiving intravitreal brolucizumab injections with STTA during loading at Saitama Medical University Hospital\'s Eye Center from May 2021 to June 2022 were analyzed. Complete regression rates of polypoidal lesions were assessed using indocyanine green angiography 12 weeks post-treatment initiation.
RESULTS: Nineteen patients (19 eyes) participated. Best-corrected visual acuity significantly improved at eight weeks compared to baseline. No significant intraocular pressure increases occurred throughout the loading phase, while central foveal and choroidal thickness significantly reduced at 4, 8, and 12 weeks. Subretinal fluid was present in all patients before treatment, rapidly resolving post-intravitreal brolucizumab injections and STTA, with residual rates of 36.8% (seven eyes) and 5.3% (one eye) at four and 12 weeks, respectively. Intraocular inflammation did not occur during the loading phase, and the complete regression rate of polypoidal lesions was 89.5% (17 eyes).
CONCLUSIONS: Combining intravitreal brolucizumab injection with STTA during the loading phase may be one treatment option for PCV management.
METHODS: In this retrospective observational study, untreated patients with PCV receiving intravitreal brolucizumab injections with STTA during loading at Saitama Medical University Hospital\'s Eye Center from May 2021 to June 2022 were analyzed. Complete regression rates of polypoidal lesions were assessed using indocyanine green angiography 12 weeks post-treatment initiation.
RESULTS: Nineteen patients (19 eyes) participated. Best-corrected visual acuity significantly improved at eight weeks compared to baseline. No significant intraocular pressure increases occurred throughout the loading phase, while central foveal and choroidal thickness significantly reduced at 4, 8, and 12 weeks. Subretinal fluid was present in all patients before treatment, rapidly resolving post-intravitreal brolucizumab injections and STTA, with residual rates of 36.8% (seven eyes) and 5.3% (one eye) at four and 12 weeks, respectively. Intraocular inflammation did not occur during the loading phase, and the complete regression rate of polypoidal lesions was 89.5% (17 eyes).
CONCLUSIONS: Combining intravitreal brolucizumab injection with STTA during the loading phase may be one treatment option for PCV management.
摘要：
背景：这项研究评估了在负载阶段玻璃体内注射布罗珠单抗与曲安奈德（STTA）胶囊联合注射治疗息肉样脉络膜血管病变（PCV）的安全性和有效性。
方法：在这项回顾性观察研究中，分析了2021年5月至2022年6月在Sa玉医科大学医院眼科中心接受STTA玻璃体内注射的未经治疗的PCV患者。治疗开始后12周，使用吲哚菁绿血管造影术评估息肉状病变的完全消退率。
结果：19例患者（19只眼）参加。最佳矫正视力在八周时与基线相比显著改善。在整个负荷阶段没有明显的眼内压升高，而中央凹和脉络膜厚度在第4、8和12周时显著降低。治疗前所有患者均存在视网膜下液,快速解决玻璃体内注射和STTA，4周和12周的残留率为36.8%(7只眼)和5.3%(一只眼)，分别。眼内炎症没有发生在负荷阶段，息肉状病变完全消退率为89.5%(17眼)。
结论：在负荷阶段将玻璃体内布罗珠单抗注射与STTA联合可能是PCV管理的一种治疗选择。
方法：在这项回顾性观察研究中，分析了2021年5月至2022年6月在Sa玉医科大学医院眼科中心接受STTA玻璃体内注射的未经治疗的PCV患者。治疗开始后12周，使用吲哚菁绿血管造影术评估息肉状病变的完全消退率。
结果：19例患者（19只眼）参加。最佳矫正视力在八周时与基线相比显著改善。在整个负荷阶段没有明显的眼内压升高，而中央凹和脉络膜厚度在第4、8和12周时显著降低。治疗前所有患者均存在视网膜下液,快速解决玻璃体内注射和STTA，4周和12周的残留率为36.8%(7只眼)和5.3%(一只眼)，分别。眼内炎症没有发生在负荷阶段，息肉状病变完全消退率为89.5%(17眼)。
结论：在负荷阶段将玻璃体内布罗珠单抗注射与STTA联合可能是PCV管理的一种治疗选择。
